Kepler Capital Markets Reiterates “€106.00” Price Target for Merck KGaA (MRK)
Merck KGaA (FRA:MRK) has been given a €106.00 ($123.26) price target by investment analysts at Kepler Capital Markets in a note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Kepler Capital Markets’ price objective would indicate a potential upside of 21.36% from the company’s previous close.
A number of other research analysts have also weighed in on the company. Goldman Sachs Group set a €92.00 ($106.98) target price on Merck KGaA and gave the company a “neutral” rating in a report on Wednesday. Commerzbank set a €100.00 ($116.28) target price on Merck KGaA and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. restated a “neutral” rating and issued a target price on shares of Merck KGaA in a report on Tuesday. Berenberg Bank set a €102.00 ($118.60) target price on Merck KGaA and gave the company a “buy” rating in a report on Thursday, August 30th. Finally, Warburg Research set a €100.00 ($116.28) target price on Merck KGaA and gave the company a “neutral” rating in a report on Tuesday, August 28th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. Merck KGaA currently has a consensus rating of “Hold” and a consensus price target of €98.71 ($114.78).
MRK stock opened at €87.34 ($101.56) on Wednesday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
See Also: Trading Strategy Methods and Types
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.